Return to Latest Recommendation
Date of publication: April 8, 2020
- Policy and Research Question
- Policy Question: Should the Philippine government introduce favipiravir as an add-on to the DOH-PSMID-recommended treatment regimens for patients with COVID-19 versus the DOH-PSMID recommended guidelines as of March 31?
- Research Questions:
- What are the current country TGs or CPGs which recommend the use of favipiravir in treating patients with COVID-19?
- What is the clinical efficacy/ effectiveness and safety of favipiravir as an add-on to the DOH-PSMID-recommended treatment regimens for patients with COVID-19 versusthe DOH-PSMID recommended guidelines as of March 31?
- Does favipiravir as an add-on to the DOH-PSMID-recommended treatment regimens represent value for money for the treatment of patients with COVID-19 versus the DOH-PSMID recommended guidelines as of March 31?
- Reviewers: Health Technology Assessment Unit, DOH
- Start of Review: March 26, 2020
- End of Review: April 8, 2020
- Evidence and Relevant Links:
- Evidence summary: Favipiravir
- Rapid review: Use of Favipiravir for treating patients with COVID-19
- HTA Council Recommendation (2020)